Healthcare & Biotech Business Grants USA 2026

What funds a healthcare or life-science company in the United States

Instrument mix of the 195 healthcare and life-science programs open on August 28, 2026, computed from the GrantCompass catalog (2 pitch competitions make up the rest). Grants are a minority of the programs but the overwhelming majority of the money; the full ranked report at /match spans all 736 US programs, and /explore is the browsable database.

The four instruments, and what each one actually pays for

How big the US health-funding landscape actually is

Federal programs a life-science company applies to first

Five federal programs account for most first non-dilutive dollars in US life sciences: NIH SBIR and STTR (Phase I and Phase II), NSF SBIR through America's Seed Fund, the federal Section 41 R&D credit, and SBA-guaranteed lending for the facility. The table below gives the current ceilings and cadence for each. NIH's September 5, 2026 standard receipt date falls on a Saturday and September 7 is Labor Day, so the operative deadline is Tuesday, September 8, 2026.

Why NIH SBIR is more legible than a discretionary grant

Where the money differs by sub-vertical

"Healthcare" is not one funding market. A gene-therapy company, a CLIA diagnostics lab, a surgical-robotics manufacturer, a clinical-decision-support SaaS company and a three-clinic dental group all appear under the same industry label and are funded by entirely different machines, on different timescales, at scales that differ by two orders of magnitude. A therapeutics company reads a $2,153,927 Phase II ceiling as a real financing event; a home-health agency will never be eligible for a dollar of it and needs an SBA 504 loan instead. The table below is the fastest way to find which of the six worlds you are in; the sections that follow give each one its own named programs.

Therapeutics: drugs, biologics, cell and gene therapy

Therapeutics is the sub-vertical the NIH SBIR system was built around, and it is the only one where a single non-dilutive award reaches seven figures. The path is NIH SBIR Phase I at $323,090 for feasibility and mechanism work, then NIH SBIR Phase II at $2,153,927 for IND-enabling studies, submitted to the disease institute that owns your indication. Academic founders still holding a faculty appointment use NIH STTR Phase I and STTR Phase II at the same ceilings instead.

Two federal alternatives sit alongside NIH for therapeutics with a specific profile. ARPA-H funds high-risk health technology through Innovative Solution Openings, typically $1 million to $50 million, awarded as Other Transaction agreements rather than grants. BARDA DRIVe funds work with a health-security or pandemic-preparedness angle on a rolling basis. For an ultra-rare cancer indication — conventionally fewer than 1,000 US patients — FDA's ultra-rare cancers cooperative agreement is the regulatory-intelligence route, though its RFA-FD-26-004 cycle closed June 15, 2026. At the state level, Connecticut Innovations Pre-Seed and the NCBiotech Small Business Research Loan ($150,000–$350,000) are built for pre-clinical companies specifically.

Diagnostics: assays, biomarkers and laboratory tests

Diagnostics companies apply to the same NIH mechanisms as therapeutics but to different institutes, and the institute choice usually decides the outcome. An oncology assay goes to the National Cancer Institute; an imaging-based or instrument-based test goes to the National Institute of Biomedical Imaging and Bioengineering; a rapid infectious-disease test goes to the National Institute of Allergy and Infectious Diseases. The award ceilings are identical to therapeutics — $323,090 for Phase I under NIH SBIR — but the review panel and the commercialization questions are not.

The gap diagnostics founders underestimate is everything after analytical validation: a CLIA-certified laboratory, clinical validation cohorts, and the reimbursement dossier. NIH grants scope to the science and rarely cover that. Two federal programs sit outside the NIH lane and are worth knowing: NSF SBIR Phase I at $305,000 when the innovation is the sensing hardware rather than the biology, and the CDC/NIOSH occupational-safety research cooperative agreement ($150,000–$975,000) for tests aimed at workplace exposure. State non-dilutive seed money that fits a diagnostics timeline includes the Maine Technology Institute Seed Grant ($5,000–$50,000), SCRA Technology Startup Grants ($25,000–$50,000) and the TEDCO Seed Fund in Maryland.

Medical devices, imaging and surgical robotics

Medical devices straddle two federal systems, and choosing between them is the first real decision. When the clinical application is the innovation, the home is the National Institute of Biomedical Imaging and Bioengineering through NIH SBIR Phase I at $323,090. When the hardware, materials or manufacturing process is the innovation and the medical use is one application among several, NSF SBIR Phase I at $305,000 puts the proposal in front of engineers rather than clinicians. NSF STTR Phase I covers the same ground where a university partner holds the core technology.

Device companies also get access to a manufacturing support layer that pure-therapeutics companies do not use. The NIST Manufacturing Extension Partnership provides subsidized engineering consulting through a center in every state, Manufacturing USA institute project calls run $1 million to $12 million-plus collaborative projects, and state programs such as the Connecticut Manufacturing Innovation Fund Voucher ($6,250–$100,000) and the Michigan Industry 4.0 Technology Implementation Grant (up to $25,000 at 50% match) pay for production tooling and process work. For the facility itself, the MassDevelopment Emerging Technology Fund lends up to $4,000,000. Deeper coverage of that layer sits on our manufacturing grants hub.

Digital health, health IT and clinical AI

Digital health is the sub-vertical most often mis-served by biotech funding advice, because the money behaves differently: awards are smaller, the science reviewers are less certain, and the fastest cash usually comes from the tax layer rather than a grant. Inside NIH, clinical informatics and data-science tools go to the National Library of Medicine, and an AI tool aimed at one condition goes to that condition's institute. Outside NIH, NSF SBIR Phase I ($305,000) and Phase II ($1,250,000) review AI and platform work as engineering, and ARPA-H issues SBIR contracts of up to $600,000 for Phase I and $3.5 million for Phase II.

One eligibility rule catches venture-backed digital health companies specifically: NSF SBIR excludes any company majority-owned by a venture capital operating company, hedge fund or private equity firm. NIH imposes no equivalent ownership restriction. Because digital health companies are payroll-heavy and pre-revenue, the federal Section 41 R&D credit with its $500,000 annual payroll-tax offset is usually the single largest and fastest source of cash on this list. State innovation vouchers such as the Illinois Innovation Voucher (up to $75,000) and seed investors such as Ben Franklin Technology Partners ($50,000–$500,000) fill in around it. Software-first companies should also read our technology and software grants hub.

Health services and care delivery: the sub-vertical with no research money

Clinics, dental practices, home-health agencies, behavioral-health providers, medical transport and long-term care are all "healthcare" in every industry taxonomy, and none of them have a research-grant lane. There is no NIH SBIR for opening a second clinic. Being told otherwise is the most common way this category wastes months. The honest answer is that care-delivery businesses are financed like other operating businesses, with three instruments: government-guaranteed debt, place-based tax incentives and community lending.

The core routes are the SBA 7(a) loan (up to $5,000,000 for fit-out, acquisition and working capital), the SBA 504/CDC loan (up to $5,500,000 for real estate and long-lived equipment, at below-market fixed rates), the SBA Express Loan (up to $500,000 on a faster decision), the SBA Microloan (up to $50,000) and SBA CAPLines for working-capital lines. Rural providers can use the USDA Community Facilities Direct Loan and Grant, which does include grant funding of up to 75% of project costs for eligible facilities, and the USDA Business and Industry Loan Guarantee up to $25,000,000. Practices in designated low-income census tracts can be financed through the New Markets Tax Credit, which delivers below-market loans of $2 million to $20 million.

Biomanufacturing, reagents and life-science tools

Companies that make the inputs — media, reagents, bioprocess equipment, contract manufacturing capacity — sit at the intersection of life sciences and industrial policy, and they are eligible for a funding stack that pure-therapeutics companies cannot reach. NSF SBIR treats biomanufacturing as an engineering priority. DOE STTR Phase I ($200,000–$250,000) and the DOE Office of Science financial assistance program ($50,000–$5,000,000 per year) fund bioprocess and biological-systems research. Manufacturing USA institute project calls fund collaborative production-scale work.

The bio-based route adds two USDA programs that most life-science founders have never heard of: the USDA Biorefinery, Renewable Chemical and Biobased Product Manufacturing Assistance program guarantees up to 80% of a loan for biobased manufacturing facilities, and the USDA BioPreferred program is a certification that creates federal procurement preference rather than cash. On the state side, capital-intensive biomanufacturing expansions are exactly what negotiated packages are designed for: the Next New Jersey Manufacturing Tax Credit reaches 25% of capital investment, and the South Dakota REDI Fund lends up to $3,000,000.

NIH SBIR and STTR — the core funding source for biotech

The National Institutes of Health runs the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs across its 27 institutes and centers, and together they are the dominant source of non-dilutive early-stage funding for US biomedical companies. The size of that pot is not a policy choice made each year: by statute, every federal agency with an extramural R&D budget above $100 million must set aside 3.2% of it for SBIR, and agencies above $1 billion set aside a further 0.45% for STTR (both figures as of FY2025; they were 2.5% and 0.3% in FY2010). Across the whole federal government, SBIR and STTR obligations totalled $5.06 billion in FY2022 — $4.4 billion SBIR plus $662.3 million STTR — the most recent year with published SBA annual-report data as of December 2025. NIH is the largest health-research participant in that system. Understanding how it works — study sections, institute selection, and the receipt-date calendar — matters more than any line-by-line application tip. The generic mechanics of SBIR and STTR are covered on our SBIR and STTR guide for startups; this page stays on what is specific to NIH and to life sciences.

Phase I vs Phase II: what you're actually applying for

A critical fact that trips up first-time applicants: Phase II is not an automatic continuation of Phase I. It is a fully competitive re-application submitted to the same NIH institute, peer-reviewed by a study section from scratch, and scored against that cycle's pool of Phase II applicants. A borderline Phase I score does not preclude a strong Phase II, and a perfect Phase I score does not guarantee Phase II funding. The Phase II review places significantly more weight on the commercialization plan: study sections increasingly expect FDA pathway clarity, identified manufacturing partners, and letters of intent from strategic partners or early customers.

The NIH award ceiling is a guideline, not always a hard cap

The figures $323,090 (Phase I) and $2,153,927 (Phase II) are the SBA-published budget guidelines that apply across the SBIR and STTR programs, not an absolute statutory maximum for every NIH topic. NIH institutes may issue funding opportunities whose topics carry approved waivers permitting larger budgets, and individual applicants may request more than the guideline with prior institute approval. Practically, this means two applicants to two different NIH institutes in the same cycle can face different caps for the same mechanism.

The operational rule that follows: read the budget section of the specific funding opportunity you are applying to, not a summary page, before you build the budget. A budget request above the guideline without prior written NIH approval is an avoidable administrative rejection, and it is the kind of error that costs a full four-month cycle rather than a score. Requests up to the guideline amount need no special justification. Indirect costs are reimbursed at the company's negotiated Facilities and Administrative rate, or at a de facto 26% for a company with no negotiated rate, and the 7% fee sits on top of direct plus indirect costs.

NIH standard receipt dates and the weekend and holiday rule

NIH SBIR and STTR applications run on three standard receipt dates a year: September 5, January 5 and April 5. These dates are fixed in the standard due-date table and are not at a program officer's discretion. One rule catches applicants every few years: when a standard due date lands on a weekend or a federal holiday, it moves forward. In the National Institute of Mental Health's own wording, "When application due dates fall on a weekend or Federal holiday, they are extended to the next business day."

That rule is live right now. September 5, 2026 is a Saturday, and Monday September 7, 2026 is Labor Day, so the operative NIH receipt date for that cycle is Tuesday, September 8, 2026. The two dates after it need no adjustment: January 5, 2027 is a Tuesday and April 5, 2027 is a Monday. Do not treat the extra weekend as slack. Grants.gov and eRA Commons validation errors surface after submission, and the extension moves the late-application window forward with the deadline rather than adding to it.

What changes for NIH applicants in FY2027: per-company proposal limits

The Small Business Innovation and Economic Security Act (P.L. 119-83), signed April 13, 2026, reauthorized SBIR and STTR through September 30, 2031 after a six-month lapse in program authority. It also introduces a constraint that changes portfolio strategy for prolific applicants. Per the Congressional Research Service, "Beginning in FY2027, the law requires that the director of a federal agency's SBIR or STTR program set a limit on the maximum number of proposals a small business can submit in response to Phase I and Phase II solicitations in a single fiscal year."

Agencies must publish those limits ahead of each fiscal year. For a life-science company that has been submitting the same core technology to three or four NIH institutes per cycle as a hedge, the practical implication is direct: from FY2027 that hedge may not be permitted at full width, and institute selection stops being a low-cost bet and becomes a real allocation decision. Check the limit your target agency publishes before planning a multi-institute submission year.

How study sections and scoring actually work

Paylines and the five scoring criteria

A payline is the percentile rank at or below which an NIH institute expects to fund applications in a given fiscal year, and it is set institute by institute rather than centrally. Paylines vary widely and move year to year, so the only reliable number is the one published on your target institute's own funding-policy page for the current fiscal year. Treat any single site-wide "NIH funds the top X percent" figure — including one on a page like this — as an average that may not describe the institute you are actually applying to.

The five scoring criteria are Significance, Innovation, Approach, Investigators and Environment. Each is scored 1 to 9 by each assigned reviewer, and those are combined into the single impact score. For SBIR and STTR applications specifically, Approach carries the heaviest practical weight: a reviewer who doubts that the proposed experiments can answer the question will score the application down no matter how compelling the significance narrative is. That is why specific, measurable aims with explicit go/no-go milestones outscore aims written as areas of investigation.

Email the NIH Program Officer before you write anything

NIH Program Officers are the scientific staff at each institute who manage its grants portfolio, and unlike funding staff at most agencies they are explicitly reachable by applicants before submission. A short email — three paragraphs covering the technology, the target patient population, and the proposed Phase I aims — usually earns a substantive reply within a week. The Program Officer can say whether the project fits the institute's current priorities and, more usefully, whether it belongs at that institute at all.

The arithmetic is why this is the first step rather than a nicety. A Phase I application takes roughly 160 hours to prepare and a Phase II roughly 220 hours. A two-hour email exchange that redirects the application from the wrong institute to the right one, or that reveals the scope is out of range for the current solicitation, protects the entire remaining investment. The same conversation is where you confirm whether the institute accepts Fast Track applications, whether your topic carries a budget waiver, and what the institute's current payline looks like.

Institute selection is the single biggest strategy decision

NIH SBIR is not one competition. It is a set of separate competitions run by separate institutes, each funding different topic areas, setting its own payline, and drawing on different study-section reviewers. A cancer-diagnostics company has a plausible home at the National Cancer Institute, at the National Institute of Biomedical Imaging and Bioengineering if the innovation is an imaging device, and potentially at the National Heart, Lung, and Blood Institute if the clinical context is cardio-oncology. The same application scores differently in each.

Choose the institute whose study section contains reviewers who already understand your science, your clinical setting and your commercial landscape — those reviewers do not have to be persuaded that the problem matters, which frees the application to argue the thing that is actually in doubt. From FY2027, P.L. 119-83 requires agencies to cap how many proposals one small business may submit per fiscal year, so submitting the same technology to several institutes as a hedge may not remain available at full width. The table below maps therapeutic areas to their natural institute homes.

NIH institutes by therapeutic area

Resubmission: NIH runs on an A1 culture

An NIH application that is reviewed and not funded is not a dead application. Reviewers' written critiques — the summary statement — are returned within weeks of the funding decision, and applicants are permitted one amended resubmission, designated A1, carrying a one-page introduction that responds to each concern raised. This is a standing feature of the NIH system rather than an exception granted on appeal, and a large share of funded small-business awards are A1 submissions rather than originals.

Two practical consequences follow. First, budget the calendar for two cycles, not one: an unfunded September application resubmitted at the January receipt date is the normal path, not a failure mode. Second, write the A1 introduction as a point-by-point response. Reviewers of an A1 are given the previous summary statement, and an introduction that concedes and fixes a specific methodological objection moves a score further than a defensive restatement of the original argument. A resubmission that changes nothing material is the one situation where the A1 slot is genuinely wasted.

SAM.gov and eRA Commons registration: start six weeks early

NIH SBIR and STTR applications are submitted through Grants.gov, which requires three separate registrations that do not happen instantly: a Unique Entity Identifier and an active registration in SAM.gov (renewed annually), an eRA Commons account for both the organization and the Principal Investigator, and an active Grants.gov account. New SAM.gov registrations commonly take 7 to 21 days to process, and a registration that lapses inside the submission window produces a rejected application with no route of appeal before the next receipt date.

Begin at least six weeks before the receipt date you are targeting — for the Tuesday, September 8, 2026 cycle, that meant starting in late July 2026. Our step-by-step SAM.gov registration guide walks through the current process end to end, including the entity-validation step that is the usual cause of a multi-week delay.

SBIR vs STTR for academic spinouts

The STTR bottleneck is the technology transfer office, not the science

The step that most often costs an STTR applicant a full cycle is the collaboration agreement with the partner institution. University technology transfer offices are chronically under-resourced, and a first-time STTR collaboration agreement — which must allocate intellectual property rights between the company and the institution as well as specify the minimum 30% subcontract — commonly takes 6 to 10 weeks to negotiate and execute. It cannot be back-dated after submission.

Work backwards from the receipt date. For the September 2026 NIH cycle, whose operative deadline is Tuesday, September 8, 2026, negotiations needed to open no later than the start of June 2026. Two things shorten the path: asking the technology transfer office whether it has an existing STTR template agreement (many do, and using it removes most of the negotiation), and settling the IP allocation with your own counsel before the first meeting rather than discovering the disagreement inside the institution's queue.

NIH SBIR and STTR side by side

The two mechanisms share award ceilings and receipt dates and differ on exactly two things that matter: who the Principal Investigator works for, and whether a research institution must be part of the project. Everything else in the comparison below follows from those two rules. Grant activity codes differ too, which matters when searching for opportunities: SBIR uses R43 for Phase I and R44 for Phase II, STTR uses R41 and R42.

Timeline: NIH SBIR application to first check

Plan the cash gap, not just the application

The consequence of a 9-to-13-month path is that an NIH award funds the year after the one a company is currently living in. A pre-revenue therapeutics or device company that submits in September 2026 should assume no NIH cash before mid-2027, and should not build a hiring plan against it. This is the single most common planning error on the non-dilutive path, and it is why the tax and state layers on this page matter: the federal Section 41 payroll-tax offset produces cash quarterly, and several state programs pay in weeks rather than quarters.

Program authority (verified August 28, 2026): SBIR and STTR were reauthorized on April 13, 2026 under the Small Business Innovation and Economic Security Act (P.L. 119-83), which extends both programs through September 30, 2031 and ended a six-month lapse in authority that began when the previous authorization expired on September 30, 2025. NIH's 2026 omnibus solicitation covers the standard three receipt dates — September 5, 2026 (operative date Tuesday, September 8, 2026), January 5, 2027 and April 5, 2027. Confirm the live announcement at your target institute before submitting; institute-specific opportunities can carry their own dates that override the standard table.

NSF SBIR for life-sciences engineering

NSF's America's Seed Fund backs foundational innovation across hard science and engineering domains — including life-sciences engineering. NSF Phase I awards up to $305,000 (slightly below NIH's $323,090) and Phase II up to $1,250,000 (significantly below NIH's $2.15M). Despite the lower ceiling, NSF is the right choice when the primary innovation is an engineering or physical-science breakthrough that enables medical applications, rather than a biological or therapeutic advance itself.

The NSF Project Pitch is a gate, not a formality

NSF uses a two-stage process. First, submit a 3,500-character Project Pitch online at seedfund.nsf.gov. NSF program directors review each pitch and either invite a full proposal or decline it, and only invited applicants may submit — an uninvited full proposal is returned without review. That makes the pitch, not the proposal, the real gate, and it is the cheapest stage at which to be told no. GrantCompass does not publish an NSF invitation or funding rate here; NSF itself is the only reliable source for current figures, and they move between solicitations. Pre-submission calls with NSF program directors are available and are the single highest-value preparation step before writing the pitch.

Note on NSF SBIR current status (re-verified July 2026): NSF paused new Project Pitch submissions on April 16, 2026, citing internal processing delays. Per NSF's own SBIR/STTR program page, Project Pitch submissions reopened June 2, 2026 under current solicitations NSF 26-510 and NSF 26-511. If you are reading an older guide that still says "paused," that information is stale — check seedfund.nsf.gov/solicitations for the live deadline calendar before submitting.

FDA cooperative agreements for ultra-rare cancer therapeutics

The FDA's Office of Orphan Products Development funds research through cooperative agreements — a funding mechanism where FDA program staff actively collaborate with and provide regulatory guidance to awardees, rather than passively funding external research. This makes FDA cooperative agreements distinctly valuable for companies navigating the regulatory pathway for rare diseases, where FDA expertise is as valuable as the funding itself.

Three ways an FDA cooperative agreement differs from an NIH grant

When the FDA pathway fits better than NIH SBIR

The choice between an FDA cooperative agreement and an NIH SBIR grant comes down to which uncertainty is binding. If the open question is scientific — does the molecule engage the target, does the assay detect the biomarker reliably — NIH peer review by disease-area scientists is the right instrument. If the open question is regulatory — how do you design a trial FDA will accept as adequate evidence for a disease with fewer than 1,000 patients, where a conventional Phase III is impossible — then FDA's co-investigation model is worth more than the grant dollars, because it puts the agency that will judge the eventual application inside the research while it is still being designed.

Cooperative-agreement mechanics and pre-application consultations

Pre-application consultations and the Grants.gov submission stack

Non-dilutive routes that are not NIH

NIH is the largest health-research funder in the United States, and it is also the slowest and the most crowded. Four other routes carry real money for life-science companies and are systematically under-applied: the Advanced Research Projects Agency for Health, BARDA's health-security programs, the health-adjacent programs at agencies that are not health agencies at all, and state programs that pay a company a second time for winning a federal award. A fifth route — disease foundations and venture philanthropy — is real but is not indexed in the GrantCompass catalog, and this page says so rather than pretending otherwise. Of the 195 healthcare and life-science programs open on August 28, 2026, 44 are federal and 118 are state; almost every founder we see has looked at part of the first group and none of the second.

ARPA-H: health technology funded like DARPA

The Advanced Research Projects Agency for Health, part of the US Department of Health and Human Services, funds high-risk health technology on a model borrowed from DARPA rather than from NIH. It does not run study sections and it does not use the standard receipt-date calendar. It publishes Innovative Solution Openings continuously on SAM.gov, and awards typically run $1 million to $50 million as Other Transaction agreements — a contracting instrument, not a grant, with milestone-based payments and active program-manager direction.

ARPA-H also runs its own SBIR and STTR track, and its award sizes are materially larger than NIH's. Per ARPA-H's own small-business page, "Awards are generally issued in the form of contracts of up to $600K for Phase 1 and $3.5M for Phase 2." The eligibility rules are the standard SBIR set: no more than 500 employees, majority ownership by US citizens or another US-based small business, and all work performed in the United States, with the Principal Investigator more than 50% employed by the small business for SBIR. The trade-off against NIH is directional control: an ARPA-H program manager can redirect scope mid-project in a way an NIH institute cannot.

BARDA and the health-security route

The Biomedical Advanced Research and Development Authority funds medical countermeasures — vaccines, therapeutics, diagnostics and devices aimed at chemical, biological, radiological, nuclear and pandemic threats. Its early-stage front door is BARDA DRIVe, the Division of Research, Innovation and Ventures, which runs rolling open calls and prize challenges rather than fixed receipt dates and works with an accelerator network rather than a single application portal.

The strategic point for a life-science founder is that BARDA reframes technologies that look unfundable at NIH. A rapid sepsis diagnostic, a broad-spectrum antiviral, a wearable early-warning sensor or a needle-free delivery platform may compete poorly against disease-specific applications at a disease institute and compete very well against a preparedness mission. BARDA also funds far later than NIH does, through advanced development and procurement, which means a first DRIVe engagement can lead to a substantially larger relationship than a Phase II ceiling. Check drive.hhs.gov for current open calls; there is no annual deadline to miss.

Federal agencies that fund health work without being health agencies

Six non-health federal programs in the GrantCompass catalog fund work that life-science companies do, and their review panels are usually less crowded than NIH's. The National Science Foundation reviews the engineering underneath a medical product: NSF SBIR Phase I at $305,000, Phase II at $1,250,000, and NSF STTR Phase I at $305,000. The Department of Defense funds biotechnology directly through DoD SBIR Phase II (up to $2,000,000) and through AFWERX SBIR Phase I (up to $250,000), both of which list biotechnology as an eligible domain.

Disease foundations and venture philanthropy — real, and not in our catalog

A route this page will not pretend to index: disease-specific foundations fund company research directly, on terms that look nothing like a federal grant. Organizations such as the Cystic Fibrosis Foundation, the Michael J. Fox Foundation for Parkinson's Research, the Leukemia & Lymphoma Society and the Alzheimer's Drug Discovery Foundation make milestone-based research awards to for-profit companies working on their disease, frequently with a revenue- or royalty-sharing term attached in exchange for capital that arrives earlier and with more disease expertise than a federal cycle can offer.

GrantCompass does not currently index disease-foundation research awards, and none of the figures on this page include them. We say that rather than list a plausible-sounding award size we have not verified. If you work in an indication with an organized patient foundation, treat its research or "therapeutics accelerator" program as a first-tier funder alongside NIH, go to that foundation's own research-funding page for the current terms, and expect the diligence to be scientific rather than administrative. The catalog covers 1 foundation-level program in this slice, which is a gap in our data and not a description of the market.

State SBIR and STTR match programs: getting paid twice for one award

At least nine states pay a company a second, separate award for winning a federal SBIR or STTR — either as a match on the federal money or as a grant for the proposal work itself. These are the highest-return-per-hour programs in the entire healthcare catalog, because the scientific case has already been made and won: the state application is largely administrative. They are also among the least claimed, because they are announced by state economic-development agencies rather than by the federal agency that made the award.

Claim the state match before writing the next federal proposal

State life-science and innovation funds

State programs are 118 of the 195 healthcare and life-science programs open on August 28, 2026 — nearly three times the federal count — and they behave differently from federal money in three ways that matter. They decide in weeks rather than quarters. They are frequently structured as convertible notes, recoverable grants or loans rather than pure grants, so read the instrument before assuming the money is non-dilutive. And they almost always carry a residency or in-state-spending condition, which makes them a function of where the company is incorporated and where the lab actually sits. The three groups below cover what a life-science company can use at each stage.

Seed, proof-of-concept and innovation-voucher programs

These are the state programs designed for a company that has science but not yet a federal award, and most of them decide in under a quarter. Connecticut runs two: the Connecticut Innovations Pre-Seed Investment Program (up to $150,000) and the Proof-of-Concept Fund ($50,000–$100,000 as a convertible note). Pennsylvania's Ben Franklin Technology Partners invests $50,000–$500,000 through four regional offices. South Carolina's SCRA Technology Startup and Acceleration Grants are $25,000–$50,000 and explicitly non-dilutive.

Smaller and faster options include the South Dakota Proof of Concept Program (up to $25,000), the Nebraska Innovation Fund Prototype Grant (up to $150,000), the Maine Technology Institute Seed Grant ($5,000–$50,000), the TEDCO Rural Business Innovation Initiative ($25,000) and the Illinois Innovation Voucher (up to $75,000), which pays a university or research institution to do work on the company's behalf. Delaware's EDGE Grant reaches roughly $175,000. Equity and hybrid routes include the TEDCO Seed Fund, the California IBank Venture Capital Program, NJ Accelerate (up to $250,000 plus rent support), gener8tor ($100,000 for equity) and Founders First Capital Partners ($25,000–$250,000 revenue-based). Massachusetts companies should diary MassVentures START, which reopens February 1, 2027 and runs to $500,000 at its top tier.

Technology-development loans and growth capital

The instrument that funds a lab build, a pilot production line or a bridge between award cycles is usually a state loan rather than a grant, and the rates are typically below market because the lender is an economic-development agency rather than a bank. North Carolina runs the two most life-science-specific: the NCBiotech Small Business Research Loan ($150,000–$350,000) and the NCBiotech Strategic Growth Loan (up to $650,000), both on quarterly rounds with pre-application by invitation after an eligibility review.

Larger facility financing runs through the MassDevelopment Emerging Technology Fund (up to $4,000,000, rolling), the West Virginia First Small Business Growth Program ($1,000,000–$7,500,000), the JobsOhio Growth Fund Loan ($500,000–$5,000,000), the South Dakota REDI Fund (up to $3,000,000, forgivable in part) and the Pennsylvania Industrial Development Authority loan program. Mid-sized options include Advantage Illinois (up to $2,000,000 participation), the Oregon Business Development Fund (up to $2,000,000), the Oregon Entrepreneurial Development Loan Fund (up to $1,000,000), the Virginia VSBFA Economic Development Loan Fund (up to 40% of a project or $1,000,000), the Wisconsin Technology Development Loan and the South Dakota Works Financing Program.

Investor-side credits that pull outside capital into a life-science company

A category most founders overlook because the credit goes to somebody else: several states give the investor a tax credit for putting money into a qualified in-state technology or life-science company. The company receives no cash directly, but the credit changes the arithmetic of the round — a 25% to 40% credit is a material improvement in an angel's expected return, and it is a concrete reason for a local investor to write a check they were undecided about.

Maryland's Biotechnology Investment Incentive Tax Credit is the most biotech-specific, refunding 33% to 75% of an investor's investment in a qualified Maryland biotechnology company, with the company application due March 31 and the investor application April 30 each year. Broader equivalents include the Indiana Venture Capital Investment Tax Credit (25–30%, up to $1,500,000), the Kentucky Angel Investment Tax Credit (25–40%), the Minnesota Angel Tax Credit (25% and refundable), the Connecticut Angel Investor Tax Credit (25%, up to $500,000), the Wisconsin Angel Investment Tax Credit (25%, capped at $250,000 a year) and the New Mexico Angel Investment Tax Credit (up to $62,500). Companies siting a facility in a designated tract can also raise against the Qualified Opportunity Zone incentive, which has no cap and scales with the investor's deferred gain.

Federal R&D tax credits for biotech companies

The Section 41 Research and Development Tax Credit is often described as a "tax credit," which undersells its relevance to pre-revenue biotech companies. The most important version for early-stage life-sciences founders is the Qualified Small Business payroll-tax offset — a mechanism that converts what would otherwise be a future income-tax credit into real cash against current payroll obligations, even before the company earns its first dollar of profit.

How the payroll-tax offset works for a pre-revenue biotech

What counts as a qualified research expense in a life-science company

Section 174 capitalization — the cash-flow wrinkle

Building a defensible R&D credit claim in biotech

An R&D credit claim in a life-science company is documentation work as much as tax work, and the three items most often challenged are predictable: wages for researchers who also did non-qualifying work such as clinical operations or regulatory submissions; contract research organization invoices that do not separate experimental activity from production; and supply costs for materials consumed in both qualifying and non-qualifying work. Contemporaneous records — time tracking, lab notebooks, experimental protocols, project management logs — are markedly stronger than records reconstructed after the fact.

The boundary that costs biotech companies the most money is clinical trial spend. Pre-clinical work — cell assays, animal studies, formulation development — clearly qualifies. Phase I and Phase II clinical costs aimed at establishing basic safety and proof of concept frequently qualify, because genuine technical uncertainty remains. Phase III costs aimed at obtaining approval once efficacy is established generally do not, because the uncertainty being resolved is regulatory rather than technological. Many companies respond to that complexity by excluding all clinical costs, which under-claims the credit. The detail below sets out the four-part test as it applies in practice.

Audit exposure and contemporaneous documentation

The four-part test and the clinical-trial boundary

State R&D credits with biotech bonuses

The federal Section 41 credit stacks with state research credits, and in several biotech hubs the state version carries a feature built specifically for pre-revenue life-science companies. Twenty states in the GrantCompass catalog run a research credit that names biotechnology or life sciences as an eligible industry, with headline rates from 5% to 30%. Rate alone is misleading, though: what decides whether a pre-revenue company sees cash is refundability and carryforward. Massachusetts converts unused credits into a 90% cash refund for companies certified by the Massachusetts Life Sciences Center — the single most valuable state provision in US biotech. Hawaii's credit is refundable outright. California pays nothing until there is tax to offset, but carries forward indefinitely and accepts any entity type, including LLCs. The three sections below cover Massachusetts and California in detail and then list every state credit in the catalog with its rate.

Massachusetts: the MLSC 90% refundable credit

The Massachusetts credit is C-corporation only — the gate that catches LLCs

How a Massachusetts biotech LLC converts to C-corp for the MLSC credit

A Delaware LLC taxed as a partnership — the default structure for many early biotech companies — generates zero Massachusetts R&D credit, because partnerships and LLCs treated as partnerships are excluded from the credit statute. Conversion to a C-corporation under Delaware law is a statutory merger rather than a rebuild, and it is a step most venture investors want taken before a Series A in any case. Credits begin accruing on Massachusetts research expenses only from the conversion forward; expenses incurred as an LLC do not generate credits retroactively, which is why the timing of the conversion is worth real money to a company spending $1 million to $3 million a year in state.

MLSC certification timing and the university research rate

The 15% Massachusetts university research rate is under-used

Massachusetts pays a 15% credit on basic research payments to Massachusetts universities, against 10% on the company's own incremental in-state research. A $500,000 sponsored research agreement with MIT, Harvard, UMass or another Massachusetts institution therefore generates roughly $75,000 in Massachusetts credits, against roughly $50,000 for the same $500,000 spent internally at the 10% rate — a $25,000 difference for work many life-science companies were going to place with an academic laboratory anyway.

The practical move is to check the location clause before signing. A company with an ongoing academic collaboration should confirm that the sponsored-research agreement is with a Massachusetts institution and that the work is performed in Massachusetts, because both conditions drive the higher rate. This also compounds with the STTR mechanism: a company that must subcontract at least 30% of Phase I work to a research institution can direct that subcontract to a Massachusetts university and capture the 15% state rate on the portion it funds itself.

California: no cap, infinite carryforward

California offers a 15% credit on in-state qualified research expenses above the historical base (24% for payments to California universities and research consortia). There is no annual cap on the credit amount and the carryforward is infinite — unlike most state R&D credits that expire in 5 to 10 years. California's credit is available to any entity type, including LLCs, partnerships, S-corps, and C-corps, making it accessible without a conversion requirement.

Every state R&D credit a life-science company can claim

Twenty states in the GrantCompass catalog run a research credit that explicitly lists biotechnology or life sciences among eligible industries, and the rates differ by a factor of five. Rate is not the whole story: refundability and carryforward decide whether a pre-revenue company sees cash or a deferred asset. Hawaii's credit is refundable outright; Massachusetts converts to a 90% cash refund only for MLSC-certified life-science companies; California carries forward indefinitely but pays nothing until there is tax to offset. New York's Excelsior R&D credit is computed as 50% of the federal Section 41 credit, capped at 6% of qualified research expenses.

State research credits at 10% and below — and why some still beat the high-rate states

A 10% credit that pays cash is worth more to a pre-revenue company than a 24% credit that cannot be used for six years. Massachusetts is the clearest case in the table below: its headline rate is one of the lowest in the set, and its MLSC refundability provision makes it the most valuable state credit in US life sciences. Washington has no corporate income tax at all, so its relief arrives as a sales-and-use tax exemption on research machinery and equipment — a different instrument entirely, and one that lands at the moment a lab buys an instrument rather than at a tax filing.

The smallest state credits — and the biotech states with none

Four states in this catalog deliver research relief in a form that does not fit a simple percentage of in-state spend, and one major biotech state offers no research credit at all. Vermont computes its credit as 27% of the Vermont-apportioned federal Section 41 credit, so the state claim is derived from the federal one rather than calculated separately. Washington has no corporate income tax, so relief arrives as a sales-and-use tax exemption on research machinery and equipment — valuable at the moment an instrument is purchased rather than at a filing.

North Carolina, home to one of the largest US biotech clusters in Research Triangle Park, let its state research credit expire in 2015 and has not reinstated it. Companies there rely on federal SBIR and STTR, on the NCBiotech research loan and growth loan, and on job-based incentives such as JDIG instead. It is a useful reminder that cluster strength and tax generosity are not the same thing, and that a state-by-state comparison of research credits will mislead if it is read as a ranking of places to build a life-science company.

Research relief in a non-standard form: Idaho, Utah, Vermont, Washington

Four credits sit outside the standard "percentage of incremental in-state research" shape, and each is worth checking against the company's actual tax position rather than its headline rate. Idaho's 5% research credit is small but stacks cleanly on top of the federal Section 41 claim. Utah lets a company choose between a 5% incremental method and a 7.5% volume method, which favours a company whose research spend is flat rather than growing. Vermont and Washington are the two genuine outliers, for the reasons above.

SBA loans for biotech facilities and equipment

Federal grants and tax credits cover R&D expenses. They do not cover the physical infrastructure that R&D requires: laboratory buildouts, biosafety equipment, cold chain storage, cleanroom construction, or research-grade manufacturing space. The SBA 7(a) program — the agency's primary loan guarantee program — fills this gap for companies that cannot access conventional commercial credit on reasonable terms.

Apply through a Preferred Lender Program bank, not any SBA lender

Hiring, training and facility incentives for life-science employers

The least-claimed money in the healthcare catalog is not a research grant. It is the set of programs that pay a company for hiring, training and building — and they are under-claimed because they arrive after the decision rather than before it, so nobody looks for them while planning. A biotech scaling from 8 to 30 people, a diagnostics company standing up a CLIA lab, or a device manufacturer adding a production line is eligible for several of these simultaneously, in most states, with application effort measured in hours rather than weeks. Two rules apply almost everywhere: the incentive must be applied for before the hire or the training starts, and it is paid against payroll or invoices you can document.

One federal employer credit belongs here rather than anywhere else on this page, and the distinction is worth stating plainly because the name invites the opposite reading: the Small Business Health Care Tax Credit (Section 45R) is worth up to 50% of the premiums an employer pays toward its own staff's health coverage bought through the SHOP Marketplace. It is not funding for a healthcare business — a 15-person diagnostics company qualifies on exactly the same terms as a 15-person bakery, and the science is irrelevant to it. It is claimed annually on Form 8941 with the federal return rather than applied for, and it is available to employers with fewer than 25 full-time-equivalent staff and average wages under the annually indexed threshold.

State workforce training funds pay for the technicians you are about to hire

Every state in this list will pay a share of the cost of training new or existing staff, and several will design and deliver the training at no cost at all. For a life-science employer this covers exactly the roles that are hard to hire directly: laboratory technicians, quality and validation staff, manufacturing operators, and regulatory associates. The strongest deals are the fully state-funded ones — Georgia Quick Start, LED FastStart in Louisiana, AIDT in Alabama, readySC in South Carolina and the North Carolina Customized Training Program — which deliver in-kind training rather than a reimbursement.

Apprenticeship and internship credits for laboratory pipelines

Two adjacent programs are worth naming separately. The South Carolina Apprenticeship Tax Credit pays up to $4,000 per apprentice per year, which suits laboratory-technician pipelines built with a technical college. The MassCEC Clean Energy Internship Program reimburses $4,320 to $8,640 per intern and is open to life-science employers working on clean-energy-adjacent processes — relevant to biomanufacturing and green-chemistry teams in Massachusetts.

Both programs solve the same problem in different currencies. A diagnostics company standing up a CLIA laboratory or a manufacturer adding a second production shift needs technicians who do not exist in the local hiring pool, and the technical-college apprenticeship route builds them at partial cost while the internship subsidy lets a small team test a hire before committing to a full-time role. Neither is retroactive: the apprenticeship must be registered and the internship approved before the work begins, which is the same rule that governs every training program in the table above.

Job-creation tax credits: paid per employee, claimed on a return

Roughly half the states in this catalog run a per-job credit that a growing life-science company can claim, and the amounts are large enough to matter at scale. South Carolina's Jobs Tax Credit runs $1,500 to $25,000 per new full-time job depending on county tier. Tennessee's Standard Job Tax Credit is $4,500 per job and reaches $22,500 in Tier 4 counties. Rhode Island's Qualified Jobs Incentive pays $2,500 to $7,500 per job for up to ten years, and Georgia's Job Tax Credit pays $1,250 to $4,000 per job annually.

A second family is computed against payroll withholding rather than headcount, which makes it larger for companies paying scientific salaries: Kansas PEAK retains 95% of new-employee withholding, North Carolina JDIG returns 25% to 75% of it, Ohio's Job Creation Tax Credit 25% to 75%, and Illinois EDGE up to 50%. Oklahoma runs three tiers — Quality Jobs, 21st Century Quality Jobs and Small Employer Quality Jobs — paying up to 10% of new payroll for up to a decade. Others in this group: Colorado JGITC, Mississippi Jobs Tax Credit, Mississippi Advantage Jobs, Arkansas CREATE, Utah EDTIF, Indiana HBITC, Florida QTI and Iowa BIG.

Negotiated packages for a facility decision

When a life-science company is choosing between states for a manufacturing plant, a CDMO site or a headquarters relocation, the relevant instrument is not a published credit but a negotiated package — and the negotiating leverage exists only before the site decision is announced. The Texas Enterprise Fund negotiates from $500,000 into the tens of millions. Michigan's Business Development Program runs $10,000 to $10 million and above. Tennessee FastTrack typically lands $250,000 to $5 million, the One North Carolina Fund $100,000 to $5 million, and the Minnesota Job Creation Fund up to $1,000,000 as a performance-based rebate paid after the jobs and capital investment are verified.

New York offers two structural programs rather than cash: Excelsior Jobs (up to 6.85% of wages per qualifying job, with life sciences named as a targeted industry) and START-UP NY, which can eliminate state tax liability for up to ten years for a company operating on or near an eligible campus — a structure built for university spinouts. Elsewhere: Florida's Job Growth Grant Fund (up to $500,000, infrastructure and training), Oregon's Business Expansion Program, Wisconsin's Business Development Credit ($50,000–$3,000,000), Mississippi MFLEX and the Wyoming Business Ready Community program (up to $5,000,000, paid to the community for the building).

Export support for life-science companies selling abroad

Diagnostics, devices, reagents and instruments are exported far earlier in a company's life than therapeutics are, and three programs reimburse the cost of trying. The SBA State Trade Expansion Program (STEP) reimburses $2,500 to $15,000 in typical awards for trade shows, translation, compliance testing and international marketing, administered through each state. Colorado's Advanced Industries Export Grant pays up to $15,000 and names life sciences among its advanced industries. Global NY STEP reimburses $2,000 to $5,000 per activity for New York exporters. All three are reimbursement programs, so approval must precede the spend, and all three settle against receipts rather than paying in advance. Two practical notes for life-science exporters: STEP is administered state by state, so the eligible-expense list and the application window are set by your own state's trade office rather than by SBA, and international regulatory work — CE marking support, in-country registration consultants, translation of an instructions-for-use document — is frequently an eligible expense even though it is not marketing.

Lab facility energy and operating-cost programs

Wet labs, vivaria and cleanrooms are among the most energy-intensive commercial spaces per square foot, and four federal and state programs will pay for engineering work to reduce that cost. These are not life-science programs, and this page includes them for one honest reason: each explicitly lists healthcare or life sciences among eligible sectors, and facility operating cost is a real line in a pre-revenue biotech's budget. The DOE Onsite Energy Technical Assistance Partnerships provide a free industrial energy assessment. DOE Better Plants offers free technical assistance to manufacturers, life sciences included, and DOE Better Buildings Alliance does the equivalent for commercial buildings. In New York, NYSERDA FlexTech cost-shares 50% to 75% of an engineering energy study, up to $1,000,000.

Capital for clinics, practices and small health businesses

Everything above this section assumes a company doing research. Most healthcare businesses in the United States do not: they deliver care, supply it, or support it. A dental practice, an outpatient physiotherapy clinic, a home-care agency, a medical-transport operator, a behavioral-health provider or a medical billing company is a small business that happens to be in healthcare, and its funding options are the small-business options. This section collects them, because sending that reader to an NIH page wastes their time. The instruments are community lending, municipal facility grants, small private grants and free federal advisory support.

CDFI lenders: the route when a bank says no

Community Development Financial Institutions are mission-driven lenders that underwrite on cash flow and character where a bank underwrites on collateral and credit score, and they are the realistic first stop for an owner-operated clinic or care business without three years of clean financials. National options include Accion Opportunity Fund ($5,000–$250,000), Kiva U.S. (up to $15,000 at 0% interest, crowdfunded by your own network) and Honeycomb Credit ($25,000–$500,000, community-crowdfunded).

Regional CDFIs typically lend larger and know their local health market: LiftFund ($500–$1,000,000 across 14 southern and southwestern states), TruFund ($500–$1,000,000 in NY, AL, LA and TX), Coastal Enterprises ($5,000–$5,000,000 across New England), Pacific Community Ventures ($10,000–$200,000), Justine PETERSEN ($500–$150,000 in Missouri and Illinois), LEDC ($500–$250,000 in DC, Maryland and Virginia), Accompany Capital ($1,000–$350,000 for immigrant and refugee entrepreneurs in New York) and Grameen America ($2,000–$15,000 for women entrepreneurs across 17 states).

Municipal grants that pay for the clinic fit-out

Five city programs in this catalog pay real grant money — not loans — toward the physical premises of a small business, and healthcare service businesses are explicitly eligible in each. These are the closest thing to a "grant for opening a clinic" that actually exists. Chicago runs two: INVEST South/West (up to $250,000) and the Small Business Improvement Fund (up to $150,000, reimbursing permanent improvements to commercial property).

Elsewhere, the City of Dallas Small Business Assistance Program reaches $400,000, the Phoenix Business Grant Program up to $25,000, and the Philadelphia Storefront Improvement Program up to $20,000, or $30,000 for a corner property. All are geographically restricted to specific corridors or eligibility areas within their cities, so the first check is the address, not the business. Rural providers should compare the USDA Community Facilities program, whose grant component can reach 75% of project cost for eligible facilities in small communities.

Small private grants and founder programs

Private grant money in healthcare is small, competitive and mostly aimed at the founder rather than the science, but the application effort is measured in hours. The IFundWomen Universal Grant Application ($10,000–$25,000 depending on sponsor) is a single application routed to multiple corporate sponsors. The NASE Growth Grant awards up to $4,000 to members. The Freed Fellowship Grant gives $500 monthly plus a $2,500 year-end award, and the Camelback Ventures Fellowship carries a $50,000 seed grant for founders building in education and health.

Two federal routes belong here as well: the BIA Indian Loan Guarantee Program guarantees loans up to $500,000 for individuals, and the Montana Indian Equity Fund grants up to $40,000. The SBA Growth Accelerator Fund Competition ($75,000–$150,000) funds the accelerator or incubator rather than the company. Competitions such as Startup World Cup ($1,000,000 grand prize) and SXSW Pitch both list healthcare tracks — note that the Startup World Cup prize is an investment, not a grant, and is therefore dilutive.

Free federal advisory support, and what it is actually good for

Free federal business assistance is genuinely useful for a care-delivery business and genuinely limited for a research company, and it is worth knowing which is which. The SBA Small Business Development Center network and SCORE mentoring are strong on business plans, loan packaging and financial projections — exactly what an SBA 7(a) application needs — and rarely staffed for grant strategy in life sciences. Targeted networks include Women's Business Centers, Veterans Business Outreach Centers, Boots to Business, the Entrepreneurship Bootcamp for Veterans and Warrior Rising.

Two assistance programs are specific to companies with federal awards, and both are commonly left on the table. SBIR/STTR Technical and Business Assistance (TABA) adds up to $6,500 at Phase I and $50,000 at Phase II on top of the award ceiling, to buy commercialization help — and it must be requested in the proposal or by supplement, not afterwards. I-Corps at NIH provides up to $55,000 of customer-discovery training for existing NIH awardees in cohorts. For manufacturers, the NIST Manufacturing Extension Partnership supplies subsidized engineering consulting, and the SBA 8(a) Business Development Program opens sole-source federal contracting up to $4.5 million for eligible disadvantaged-owned firms.

Your funding path by founder type

The same catalog produces five very different sequences depending on who is applying. An academic founder's binding constraint is the university employment rule and the technology transfer office queue. A device founder's is whether the innovation reads as clinical or as engineering. A therapeutics founder's is institute selection. A digital health founder's is the venture-ownership rule at NSF and the size of the payroll-tax offset. A pharma or CRO's is regulatory rather than scientific. Each path below names the first three moves and the programs that go with them, in order. Read the one that matches your situation rather than all five: the sequences genuinely conflict, and the most common expensive mistake in this category is following advice written for a different kind of company. If more than one applies — a device company spinning out of a university, for instance — the academic-founder path governs the first decision, because the Principal Investigator employment rule determines which mechanism you are even eligible for.

Decision trees: where do you start?

Decision tree: which R&D tax-credit strategy fits your company

Decision tree: SBIR or STTR for an academic founder

Deeper dives: key questions answered

Three questions come up in almost every conversation with a life-science founder and are rarely answered precisely anywhere: whether federal grant money and federal tax credits can be claimed on the same research, how much of an NIH Phase I award is actually spendable on science, and which of the three receipt dates to target. Each is answered below with the specific rule rather than a general principle, with the practical consequence stated rather than left implied. The short version: grant money and tax credits stack but never on the same dollar of expense; the Phase I ceiling of $323,090 is total costs, so direct research spend is materially lower once indirect costs and the 7% fee are taken out; and the least crowded receipt date is not automatically the best one, because what varies between cycles is the institute's remaining budget rather than the score your application receives.

How do you stack multiple biotech funding sources without conflicts?

What are the realistic NIH SBIR Phase I spending patterns?

When is the best receipt date to target for NIH SBIR?

Frequently asked questions

Twelve questions come up repeatedly from US healthcare and life-science founders, grouped below by topic. The award figures are current as of August 28, 2026: NIH SBIR and STTR Phase I is capped at $323,090 in total costs and Phase II at $2,153,927, NSF SBIR Phase I at $305,000 and Phase II at $1,250,000, and the federal Section 41 payroll-tax offset at $500,000 a year for a qualified small business. Where an answer depends on a date — the NIH receipt-date calendar, the Massachusetts Life Sciences Center application window, the FDA ultra-rare cancers solicitation — the date is stated in the answer, because those are the facts that go stale fastest and the ones most often repeated after they have stopped being true.

How this page was researched

GrantCompass is an independent funding-discovery tool. It is not affiliated with the National Institutes of Health, the National Science Foundation, the Food and Drug Administration, the Small Business Administration or any other agency named on this page, and nothing here is legal, tax or financial advice. Program rules change; every figure below is dated, and the agency's own page is always the authority. This page is maintained by Khalid Hamadeh, founder of GrantCompass — corrections and additions are welcome through the about page. The three sections below set out what was verified and on what date, which programs this page includes and which it deliberately leaves out, and the primary sources used. GrantCompass publishes this method because a funding page that cannot say where its numbers came from should not be trusted with a decision that costs a founder 160 hours of application work.

What was verified, and when

Four things were checked first-hand on August 28, 2026 for this revision. NIH's weekend and holiday rule was taken from the National Institute of Mental Health's deadlines page, which states: "When application due dates fall on a weekend or Federal holiday, they are extended to the next business day." September 5, 2026 is a Saturday and September 7, 2026 is Labor Day, which makes the operative NIH receipt date Tuesday, September 8, 2026. The SBIR and STTR reauthorization details — P.L. 119-83, signed April 13, 2026, authorizing both programs through September 30, 2031 after a six-month lapse, and requiring agencies to cap per-company proposal counts from FY2027 — come from Congressional Research Service Insight IN12705, dated July 13, 2026. The ARPA-H award sizes ("contracts of up to $600K for Phase 1 and $3.5M for Phase 2") come from ARPA-H's own small-business page. The statutory set-aside percentages (3.2% SBIR, 0.45% STTR in FY2025) and the FY2022 federal totals of $4.4 billion SBIR plus $662.3 million STTR come from CRS report R48629, December 15, 2025.

All program counts, award ceilings and status flags come from the GrantCompass US catalog as of August 28, 2026 — 736 programs, of which 319 reach healthcare, biotechnology, life sciences or medical devices, and 195 of those were open. Status notes still carrying a July 18, 2026 date on this page — the NSF Project Pitch reopening, the MLSC 2026 tax-incentive window and the FDA RFA-FD-26-004 closing date — were verified on that date and were not re-checked for this revision; confirm them against the agency before relying on them.

Which programs this page includes, and which it leaves out

A broad industry-tag match returns 319 programs for this topic, and publishing all of them as a list of links would be worse than useless. This page applies four inclusion tests, and a program is listed if it passes at least one: (1) it is health or life-science specific by design — the funder or the program scope names biomedical research, life sciences, biotechnology, medical devices or health; (2) it funds research, commercialization or investment in a form a life-science company actually uses, such as an R&D credit, an SBIR match, an innovation voucher or a technology-development loan; (3) it funds the physical plant or the people a life-science company needs — facility financing, equipment, workforce training — with life sciences named as an eligible industry; or (4) it is a general small-business capital route that a care-delivery business genuinely uses, in which case it appears only in the clinics and practices section and is labeled as such.

What was excluded and why: six investor-owned utility equipment-rebate programs (ComEd, Con Edison, FPL, PG&E, Southern California Edison and Xcel Energy) list healthcare among eligible sectors but are generic commercial-building rebates with no life-science dimension, so they are named here rather than linked. Programs that are closed or between intakes are still listed where a reader needs to plan for the next cycle — MassVentures START, NYSTAR matching grants, the FDA ultra-rare cancers cooperative agreement — and are labeled with their status rather than quietly dropped. This page carries no success rates or approval odds; that question is answered on small business grant approval rates, and the generic mechanics of SBIR and STTR are on the SBIR and STTR guide, so this page does not repeat either.

Sources

Read August 28, 2026: NIMH deadlines and submission dates (nimh.nih.gov/funding/grant-writing-and-application-process/deadlines-where-to-send-applications); ARPA-H for small businesses (arpa-h.gov/explore-funding/sbir); CRS Insight IN12705, "Small Business Research Programs Reauthorized After Six-Month Lapse", July 13, 2026; CRS report R48629, "Small Business Research Programs: Selected Issues", December 15, 2025. Program records: the GrantCompass US catalog, 736 programs, snapshot of August 28, 2026. Where a figure could not be verified first-hand it is either dated to its earlier verification or omitted — this page states no NIH success rate, no disease-foundation award size and no NIH-specific annual SBIR dollar total, because none of the three could be confirmed from a primary source on the day of writing.